Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
PepsiCo Inc.
PEPConsumer StaplesGenerated Jul 5, 2026, 08:52 PM UTC
PEP (PepsiCo Inc.) analytical snapshot. Revenue grew +5.9% YoY to $91.47B. Net margin at 9.92% (contracting ▼). Return on equity 50.30%, ROA 9.12%, ROIC 20.22%. Market cap $197.12B at $144.22 per share. Trailing P/E 21.98, P/S 2.15, P/B 9.22. EV/Operating income ≈ 19.44 (EV $232.99B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -21 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Market cap
$197.12B
1.37B shares
Price
$144.22
NMS
P/E (ttm)
21.98
Revenue (FY)
$91.47B
YoY +5.9%
Net margin
9.92%
▼ 0.20pp
Free cash flow
$7.92B
8.66% margin
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score -0Stable
80% conf
Revenue grew +5.9% YoY to $91.47B. Net margin at 9.92% (contracting ▼). Return on equity 50.30%, ROA 9.12%, ROIC 20.22%.
- Revenue grew +5.9% YoY to $91.47B.
- Net margin at 9.92% (contracting ▼).
- Return on equity 50.30%, ROA 9.12%, ROIC 20.22%.
- Gross margin 54.21%, operating margin 13.10%.
- Free cash flow margin 8.66% ($7.92B).
- Net income up ▲ +1.8% YoY.
- Debt/equity 2.17, current ratio 0.90, net debt $35.88B.
- Asset turnover 0.83 — capital efficiency.
Revenue (FY)
$91.47B
YoY +5.9%
Net margin
9.92%
▼ 0.20pp
ROE
50.30%
ROA 9.12%
ROIC
20.22%
EPS (diluted)
$6.56
FY2025
Free cash flow
$7.92B
8.66% margin
Debt / equity
2.17
Cash $10.47B
Current ratio
0.90
Equity $21.38B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | $7.65B | 53.97 |
| 2017 | — | — | — | — | — | $8.11B | 48.48 |
| 2018 | $62.80B | — | 55.06 | 15.61 | 10.08 | $7.62B | 57.30 |
| 2019 | $63.52B | +1.2% | 54.67 | 16.18 | 7.65 | $7.06B | 33.46 |
| 2020 | $64.66B | +1.8% | 54.56 | 15.64 | 19.35 | $6.13B | 84.64 |
| 2021 | $67.16B | +3.9% | 55.13 | 15.32 | 10.89 | $5.42B | 54.36 |
| 2022 | $70.37B | +4.8% | 54.82 | 14.32 | 10.12 | $6.37B | 44.38 |
| 2023 | $79.47B | +12.9% | 53.35 | 14.04 | 9.59 | $6.99B | 44.42 |
| 2024 | $86.39B | +8.7% | 53.03 | 13.33 | 10.31 | $5.60B | 48.15 |
| 2025 | $91.47B | +5.9% | 54.21 | 13.10 | 9.92 | $7.92B | 50.30 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 22, 2025 | $17.92B | — | — | 10.23% |
| Jun 14, 2025 | $40.65B | — | +126.8% | 7.62% |
| Jun 14, 2025 | $22.73B | — | -44.1% | 13.63% |
| Sep 6, 2025 | $64.58B | — | +184.2% | 8.83% |
| Sep 6, 2025 | $23.94B | — | -62.9% | 23.81% |
| Mar 21, 2026 | $19.44B | — | -18.8% | 11.97% |
Revenue (annual, SEC 10-K)
2016: 0
2017: 0
2018: 62,799
2019: 63,525
2020: 64,661
2021: 67,161
2022: 70,372
2023: 79,474
2024: 86,392
2025: 91,471
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 7,647
2017: 8,106
2018: 7,623
2019: 7,061
2020: 6,133
2021: 5,417
2022: 6,373
2023: 6,991
2024: 5,604
2025: 7,924
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 30Improving
80% conf
Latest annual report (10-K) filed Feb 3, 2026. Latest quarterly report (10-Q) filed Apr 16, 2026. 15 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 3, 2026.
- Latest quarterly report (10-Q) filed Apr 16, 2026.
- 15 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference PepsiCo Inc.; broad institutional reporting.
- Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 19 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 1 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 3, 2026
Annual report
Latest 10-Q
Apr 16, 2026
8-K (recent)
15
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
19
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Feb 12, 2004 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 15, 2003 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Aug 9, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 11, 2004 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Aug 8, 2003 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| May 22, 2026 | 8-K | FORM 8-K |
| May 8, 2026 | 8-K | 8-K |
| Apr 16, 2026 | 8-K | 8-K |
| Feb 11, 2026 | 8-K | FORM 8-K |
| Feb 3, 2026 | 8-K | 8-K |
| Dec 15, 2025 | 8-K | 8-K |
| Dec 8, 2025 | 8-K | 8-K |
| Oct 9, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -12Deteriorating
70% conf
1 risk signal(s), 1 positive signal(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- Operating cash flow exceeds net income: OCF is 1.48x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Endogenous analysis: 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$91.47B
+5.9% YoY
Gross profit
$49.59B
+8.2% YoY
Operating income
$11.99B
+4.1% YoY
Net income
$9.07B
+1.8% YoY
Operating cash flow
$13.44B
+24.3% YoY
Capex
$5.52B
+6.0% YoY
Total assets
$99.47B
-1.0% YoY
Total liabilities
$81.30B
-0.7% YoY
Filing quality score
67/100
1 new disclosures
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $86.39B | $91.47B | $5.08B | +5.9% |
| Gross profit | $45.82B | $49.59B | $3.77B | +8.2% |
| Operating income | $11.51B | $11.99B | $474.0M | +4.1% |
| Net income | $8.91B | $9.07B | $164.0M | +1.8% |
| Operating cash flow | $10.81B | $13.44B | $2.63B | +24.3% |
| Capex | $5.21B | $5.52B | $311.0M | +6.0% |
| Total assets | $100.50B | $99.47B | $-1.03B | -1.0% |
| Total liabilities | $81.86B | $81.30B | $-562.0M | -0.7% |
| Long-term debt | $41.52B | $41.23B | $-291.0M | -0.7% |
| Cash & equivalents | $9.71B | $8.51B | $-1.21B | -12.4% |
| Stockholders equity | $18.50B | $18.04B | $-462.0M | -2.5% |
| Inventory | $5.33B | $5.31B | $-28.0M | -0.5% |
| R&D expense | $771.0M | $804.0M | $33.0M | +4.3% |
| SG&A expense | $34.46B | $36.68B | $2.22B | +6.4% |
| Interest expense | $939.0M | $819.0M | $-120.0M | -12.8% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Added | ProceedsFromSaleOfAvailableForSaleSecuritiesDebt |
| Removed | AccountsPayableCurrent, AccountsReceivableGrossCurrent, AccruedEmployeeBenefitsCurrent, AdvertisingExpense, AmortizationOfIntangibleAssets, AssetImpairmentCharges, CapitalizedComputerSoftwareAmortization1, CapitalizedComputerSoftwareNet, CashCollateralForBorrowedSecurities, CommonStockCapitalSharesReservedForFutureIssuance |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Material weakness in internal controls | high | 19 | 2 | Ongoing |
| Impairment charge | medium | 54 | 6 | Ongoing |
| Restructuring | medium | 124 | 10 | Ongoing |
| Off-balance sheet arrangements | medium | 37 | 8 | Ongoing |
| Related party transactions | low | 23 | 0 | NEW |
Filing signal breakdown
Red flags: 1
Positive: 1
Watch: 0
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $197.12B at $144.22 per share.
- ProPrice & TechnicalsPrice $144.22 — downtrend (below 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -21
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. PepsiCo Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewLatest annual report (10-K) filed Feb 3, 2026..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow PEP stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP● you | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |